

- HCV1b レプリコン複製細胞株の樹立 第23回中国四国ウイルス研究会、松山、2007年6月
- 147 阿部健一、池田正徳、有海康雄、團迫浩方、加藤宣之。持続的な全長 HCV RNA 複製を維持できる無血清培地を用いた細胞培養系の開発。第23回中国四国ウイルス研究会、松山、2007年6月。
- 148 矢野雅彦、池田正徳、阿部健一、團迫浩方、大越章吾、青柳豊、加藤宣之。全長 HCV RNA の複製に影響を与える日常的に摂取する栄養成分の同定および評価。第23回中国四国ウイルス研究会、松山、2007年6月。
- 149 Kato N, Abe K, Mori K, Ariumi Y, Dansako H, Ikeda M. HCV genetic variability and dynamics in long-term culture of genome-length HCV RNA-replicating cells. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
- 150 Abe K, Ikeda M, Ariumi Y, Dansako H, Kato N. Serum-free cell culture system supplemented with lipid-rich albumin for genome-length HCV RNA replication. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
- 151 Yano M, Ikeda M, Abe K, Dansako H, Ohkoshi S, Aoyagi Y, Kato N. Comprehensive analysis of the ordinary nutrients as the novel partners of anti-HCV reagents. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
- 152 Dansako H, Ikeda M, Abe K, Mori K, Ariumi Y, Kato N. A new antiviral assay system using the living cells harboring genome-length HCV RNA. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
- 153 Ariumi Y, Kuroki M, Abe K, Dansako H, Ikeda M, Wakita T, Trono D, Kato N. DNA damage sensors, ATM and Chk2, are required for hepatitis C virus RNA. 14th International Meeting on Hepatitis C Virus and Related Viruses, Glasgow, UK, September, 2007.
- 154 池田正徳、矢野雅彦、阿部健一、有海康雄、團迫浩方、加藤宣之。C型慢性肝炎に対する新しい治療剤候補の培養細胞アッセイ系を用いた探索・評価 第72回日本インターフェロン・サイトカイン学会学術集会、京都、2007年7月。
- 155 加藤宣之、阿部健一、森京子、有海康雄、團迫浩方、池田正徳。全長 HCV RNA 複製細胞の長期培養により生じる HCV の遺伝的多様性 第5回日本ウイルス学会学術集会、札幌、2007年10月。
- 156 團迫浩方、池田正徳、阿部健一、森京子、有海康雄、加藤宣之。全長 HCV-RNA の複製レベルを指標として生細胞のままアッセイできる新しい抗ウイルス剤評価システム。第55回日本ウイルス学会学術集会、札幌、2007年10月。
- 157 森京子、阿部健一、團迫浩方、有海康雄、池田正徳、加藤宣之。C型急性肝炎患者血清由来の1b型 HCV レプリコン複製細胞株の樹立 第55回日本ウイルス学会学術集会、札幌、2007年10月。
- 158 矢野雅彦、池田正徳、阿部健一、團迫浩方、大越章吾、青柳豊、加藤宣之。日常的に摂取し抗 HCV 効果を有する栄養成分の全長 HCV RNA 複製細胞を用いた網羅的探索。第55回日本ウイルス学会学術集会、札幌、2007年10月。
- 159 有海康雄、黒木美沙緒、阿部健一、團迫浩方、池田正徳、脇田隆宇、Didier Trono、加藤宣之。DNA 損傷センサー ATM と Chk2 は HCV の RNA 複製に必要な宿主因子である。第55回日本ウイルス学会学術集会、札幌、2007年10月。
- 160 有海康雄、黒木美沙緒、阿部健一、團迫浩方、池田正徳、脇田隆宇、加藤宣之。HCV の RNA 複製に必要な宿主因子 DDX3 DEAD box RNA ヘリカーゼ。第55回日本ウイルス学会学術集会、札幌、2007年10月。
- 161 Hussein H. Aly, Makoto Hijikata, Kunitada Shimotohno: A novel culture system for HCV infection and replication. 14th International symposium on hepatitis C Virus & related viruses. Glasgow UK, Sept, 2007
- 162 Kaku Goto, Koichi Watashi, Daisuke Inoue, Makoto Hijikata, Kunitada Shimotohno: The emergence of a cyclophilin inhibitor-resistant HCV variant with a mutation in NS5A. 14th International symposium on hepatitis C Virus & related viruses. Glasgow UK, Sept, 2007
- 163 村上善基、土方誠、下遠野邦忠：マイクロ RNA を用いた新規 HCV 治療法の確立。第66回日本癌学会学術総会、平成19年9月、横浜 2007
- 164 小原道法：スフィンゴ脂質とC型肝炎ウイルス複製。第49回日本脂質生化学会 2007.6.5-6。札幌
- H. 知的所有権の出願・登録状況
特になし。

研究成果の刊行に関する一覧表

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Taguwa S. et al.	Cochaperone activity of human butyrate-induced transcript 1 facilitates hepatitis C virus replication through an Hsp90-dependent pathway.	Journal of Virology	83	10427-10436	2009
Kukihara H. et al.	Human VAP-C negatively regulates hepatitis C virus propagation.	Journal of Virology	83	7959-7969	2009
Itose I. et al.	Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis.	J. Viral Hepatitis	16	844-852	2009
Oze T. et al.	Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.	J. Viral Hepatitis	16	578-585	2009
Satoh T. et al.	LGP2 is a positive regulator of RIG-I- and MDA5-mediated antiviral responses.	Proc. Natl. Acad. Sci. USA	107	1512-1517	2010
Matsushita K. et al.	Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay.	Nature.	458	1185-1190	2009
Shigemoto T. et al.	Identification of loss of function mutations in human genes encoding RIG-I and mda5: Implications for resistance to type I diabetes.	J. Biol. Chem.	284	13348-13354	2009
Takahasi K. et al.	Solution Structures of Cytosolic RNA Sensor MDA5 and LGP2 C-terminal Domains: Identification of the RNA Recognition Loop in RIG-I Like Receptors.	J. Biol. Chem.	284	17465-17474	2009
Kuroki M. et al.	Arsenic trioxide inhibits hepatitis C virus RNA replication through modulation of the glutathione redox system and oxidative stress.	Journal of Virology	83	2338-2348	2009
Yano M. et al.	Oxidative stress induces anti-hepatitis C virus status via the activation of extracellular signal-regulated kinase.	Hepatology	50	678-688	2009
Aly H.H. et al.	Strain-dependent viral dynamics and virus-cell interactions in a novel in vitro system supporting the life cycle of blood-borne HCV.	Hepatology	50	689-696	2009
Aly H.H. et al.	3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV	Biochem. Biophys. Res. Commun.	379	330-334	2009
Amako Y. et al.	Pathogenesis of hepatitis C virus infection in <i>Tupaia belangeri</i>	Journal of Virology	84	303-311	2009
Machida K. et al.	Hepatitis C Virus and Disrupted Interferon Signaling Promote Lymphoproliferation via Type II CD95 and Interleukins.	Gastroenterology	137	285-296	2009
Okamoto K. et al.	Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation.	Journal of Virology	82	8349-8361	2008
Okamoto T. et al.	A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication.	Journal of Virology	82	3480-3489	2008
Taguwa S. et al.	Human butyrate-induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication.	Journal of Virology	82	2631-2641	2008

Miyazaki M. et al.	Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I.	J. Med. Virol.	80	980-988	2008
Kohga K. et al.	Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver diseases and changes during transcatheter arterial embolization for hepatocellular carcinoma	Cancer Sci.	99	1643-1649	2008
Toyama T. et al.	A new prognostic system for hepatocellular carcinoma including recurrent cases: a study of 861 patients in a single institution.	J. Clin. Gastroenterol.	42	317-322	2008
Kurashige N. et al.	Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine.	Hepatology Research	38	450-456	2008
Kanada A. et al.	Early emergence of entecavir-resistant hepatitis B virus in a patient with hepatitis B virus/human immunodeficiency virus coinfection	Hepatology Research	38	622-628	2008
Kato H. et al.	Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5.	J. Exp. Med.	205	1601-1610	2008
Kawagoe T. et al.	Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2.	Nat. Immunol.	9	684-691	2008
Goto A. et al.	Akirins are highly conserved nuclear proteins required for NF-kappaB-dependent gene expression in drosophila and mice.	Nat. Immunol.	9	97-104	2008
Ishii K.J. et al.	Tank-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.	Nature	451	725-729	2008
Takahasi K. et al.	Non-self RNA-Sensing Mechanism of RIG-I Helicase and Activation of Antiviral Immune Responses	Molecular Cell	29	428-440	2008
Cui S. et al.	The C-terminal regulatory domain is the RNA 5'-triphosphate sensor of RIG-I	Molecular Cell	29	169-179	2008
Ariumi Y. et al.	The DNA damage sensors Ataxia-Telangiectasia Mutated Kinase and Checkpoint Kinase 2 Are Required for Hepatitis C Virus RNA Replication.	Journal of Virology	82	9639-9646	2008
Mori K. et al.	New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.	Biochem. Biophys. Res. Commun.	371	104-109	2008
Hirano K. et al.	Differential effects of calcineurin inhibitors, tacrolimus and cyclosporin A, on interferon-induced antiviral protein in human hepatocyte cells.	Liver Transpl.	14	292-298	2008
Nakamura M. et al.	Possible molecular mechanism of the relationship between NS5B polymorphisms and early clearance of hepatitis C virus during interferon plus ribavirin treatment.	J. Med. Virol.	80	632-639	2008
Ando M. et al.	Mitochondrial electron transport inhibition in full genomic hepatitis C virus replicon cells is restored by reducing viral replication.	Liver Int.	28	1158-1166	2008
Moriishi K. et al.	Critical role of PA28γ in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis.	Proc. Natl. Acad. Sci. USA	104	1661-1666	2007
Abe T. et al.	Hepatitis C Virus Nonstructural Protein 5A Modulates the TLR-MyD88-Dependent Signaling Pathway in the Macrophage Cell Lines.	Journal of Virology	81	8953-8966	2007
Mori Y. et al.	Processing of Capsid Protein by Cathepsin L Plays a Crucial Role in Replication of Japanese Encephalitis Virus in Neural and Macrophage Cells.	Journal of Virology	81	8477-8487	2007

Tani H. et al.	Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.	Journal of Virology	81	8601-8612	2007
Itose I. et al.	Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon- α and ribavirin therapy for chronic hepatitis C patients.	J. Med. Virol.	79	511-521	2007
Kumagai Y. et al.	Alveolar macrophages are the primary interferon- α producer in pulmonary infection with RNA viruses.	Immunity	27	240-252	2007
Kawagoe T. et al.	Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor-mediated immune responses but not in TCR signaling.	J Exp Med.	204	1013-1024	2007
Saito T. et al.	Regulation of innate antiviral defenses through a shared repressor domain in RIG-I and LGP2	Proc. Natl. Acad. Sci. USA	104	582-587	2007
Arimoto K. et al.	Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125	Proc. Natl. Acad. Sci. USA	104	7500-7505	2007
Tasaka M. et al.	Hepatitis C virus non-structural proteins responsible for suppression of the RIG-I/Cardif-induced interferon response	J. Gen. Virol.	88	3323-3333	2007
Dansako H. et al.	Limited suppression of the interferon- β production by hepatitis C virus serine protease in cultured human hepatocytes.	FEBS Journal	274	4161-4176	2007
Ariumi Y. et al.	DDX3 DEAD-Box RNA helicase is required for hepatitis C virus (HCV) RNA replication.	Journal of Virology	81	13922-13926	2007
Yano M. et al.	Comprehensive Analysis of the Effects of Ordinary Nutrients on Hepatitis C Virus RNA Replication in Cell Culture.	Antimicrobial Agents and Chemotherapy	51	2016-2027	2007
Aly H.H. et al.	Serum-derived hepatitis C virus infectivity in interferon regulatory factor-7-suppressed human primary hepatocytes	J. Hepatol.	46	26-36	2007
Miyanari Y. et al.	The lipid droplet is an important organelle for hepatitis C virus production.	Nat. Cell Biol.	9	1089-1097	2007
Watashi K. et al.	Anti-hepatitis C virus activity of tamoxifen reveals the functional association of estrogen receptors with viral RNA polymerase NS5B	J. Biol. Chem.	282	32765-32772	2007
Nakagawa S. et al.	Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice	Biochem. Biophys. Res. Commun.	353	882-888	2007
Inoue K. et al.	Evaluation of a Cyclophilin Inhibitor in Hepatitis C Virus-Infected Chimeric Mice In Vivo	Hepatology	45	921-928	2007
Miyatake H. et al.	Impaired ability of interferon- α -primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.	J. Viral Hepatitis	14	404-412	2006
Jinushi M. et al.	Natural killer cell and hepatic cell interaction via NKG2A leads to dendritic cell-mediated induction of CD4 CD25 T cells with PD-1-dependent regulatory activities.	Immunology	120	73-82	2006

Cochaperone Activity of Human Butyrate-Induced Transcript 1 Facilitates Hepatitis C Virus Replication through an Hsp90-Dependent Pathway[∇]

Shuhei Taguwa,¹ Hiroto Kambara,¹ Hiroko Omori,² Hideki Tani,¹ Takayuki Abe,¹ Yoshio Mori,¹ Tetsuro Suzuki,³ Tamotsu Yoshimori,² Kohji Moriishi,¹ and Yoshiharu Matsuura^{1*}

Department of Molecular Virology¹ and Department of Cellular Regulation,² Research Institute for Microbial Diseases, Osaka University, Osaka, and Department of Virology II, National Institute of Infectious Diseases, Tokyo,³ Japan

Received 21 May 2009/Accepted 27 July 2009

Hepatitis C virus (HCV) nonstructural protein 5A (NS5A) is a component of the replication complex consisting of several host and viral proteins. We have previously reported that human butyrate-induced transcript 1 (hB-ind1) recruits heat shock protein 90 (Hsp90) and FK506-binding protein 8 (FKBP8) to the replication complex through interaction with NS5A. To gain more insights into the biological functions of hB-ind1 in HCV replication, we assessed the potential cochaperone-like activity of hB-ind1, because it has significant homology with cochaperone p23, which regulates Hsp90 chaperone activity. The chimeric p23 in which the cochaperone domain was replaced with the p23-like domain of hB-ind1 exhibited cochaperone activity comparable to that of the authentic p23, inhibiting the glucocorticoid receptor signaling in an Hsp90-dependent manner. Conversely, the chimeric hB-ind1 in which the p23-like domain was replaced with the cochaperone domain of p23 resulted in the same level of recovery of HCV propagation as seen in the authentic hB-ind1 in cells with knockdown of the endogenous hB-ind1. Immunofluorescence analyses revealed that hB-ind1 was colocalized with NS5A, FKBP8, and double-stranded RNA in the HCV replicon cells. HCV replicon cells exhibited a more potent unfolded-protein response (UPR) than the parental and the cured cells upon treatment with an inhibitor for Hsp90. These results suggest that an Hsp90-dependent chaperone pathway incorporating hB-ind1 is involved in protein folding in the membranous web for the circumvention of the UPR and that it facilitates HCV replication.

Hepatitis C virus (HCV) is the major causative agent of non-A, non-B hepatitis in humans and infects approximately 170 million people worldwide (64). HCV belongs to the genus *Hepacivirus* of the family *Flaviviridae* and is classified into six major genotypes (39). The virus forms small, round, enveloped particles and possesses a genome consisting of a single positive-stranded RNA with a nucleotide length of 9.6 kb. The viral genome encodes a single precursor polyprotein consisting of approximately 3,000 amino acids, which in turn is posttranslationally processed into 10 viral proteins by host and viral proteases. The structural proteins are cleaved from the N-terminal one-fourth of the polyprotein by the host signal peptidase and signal peptide peptidase (36, 43, 44), resulting in the maturation of capsid protein, two envelope proteins, and viroporin p7. The nonstructural protein 2 (NS2) protease cleaves its own carboxyl terminus, and then NS3 cleaves the appropriate downstream positions to produce NS3, NS4A, NS4B, NS5A, and NS5B (24, 60), which form the replication complex, together with several host proteins (14, 35).

NS5A is a membrane-anchored zinc-binding phosphoprotein that appears to possess diverse functions, including the suppression of host defense and the regulation of virus replication (1, 15, 58), but its biological function remains unclear.

Several groups, including ours, have suggested that the molecular chaperone, heat shock protein 90 (Hsp90), and several cochaperones participate in the replication complex of HCV through interaction with NS5A or other NS proteins (45, 56, 65). Hsp90 is the highly conserved and ubiquitously expressed protein that acts as a key regulator for the turnover and the activities of more than 200 signaling proteins, including steroid receptors and cell-signaling kinases (66). The chaperone activity of Hsp90 contributes to the refolding of an unfolded protein in an ATP-dependent manner, and the execution of Hsp90-dependent protein folding requires the formation of a multi-chaperone complex containing other chaperones (e.g., Hsp70, Hsp104, and Hsp40) and cochaperones (e.g., p23, Hop, and immunophilins) (4, 18, 48). Geldanamycin or its derivatives, which are represented as specific inhibitors of Hsp90, can destabilize and then degrade client proteins (41, 55).

The host chaperone mechanism is involved in the folding of viral polymerase to support viral replication (6, 27). Moreover, host chaperones have been reported to play roles in the assembly of viral particles and the sorting of virus proteins (9, 32, 38). We have previously reported that Hsp90 chaperone activities and chaperone-associated proteins are required for the efficient propagation of HCV (45, 56) and that human butyrate-induced transcript 1 (hB-ind1) is involved in the propagation of HCV through interactions with NS5A and Hsp90 via the coiled-coil domain and the FXXW motif, respectively (56). hB-ind1 was first reported to be a multiple-membrane-spanning protein consisting of 362 amino acids that possesses a significant homology with a cochaperones, p23, that regulates

* Corresponding author. Mailing address: Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, 3-1, Yamadaoka, Suita-shi, Osaka 565-0871, Japan. Phone: 81-6-6879-8340. Fax: 81-6-6879-8269. E-mail: matsuura@biken.osaka-u.ac.jp.

[∇] Published ahead of print on 5 August 2009.

Hsp90 function by its cochaperone activity (11). However, the roles of hB-ind1 in the life cycle of HCV have not been precisely clarified. In this study, we investigated the role of the Hsp90-related chaperone system, including hB-ind1, in the regulation of the RNA replication and particle production of HCV.

MATERIALS AND METHODS

Plasmids. The plasmids encoding hB-ind1, NS5A, Hsp90, and FK506-binding protein 8 (FKBP8) were prepared by methods described previously (45, 56). The DNA fragments encoding hB-ind1 mutants were prepared by PCR with the introduction of a silent mutation that is resistant to the short hairpin RNA in the hB-ind1 knockdown cells, as described previously (56). The human p23 gene and glucose-regulated protein 78 (GRP78) promoter region (-151 to +22) were amplified by PCR from the total cDNA and genomic DNA of Huh7 cells, respectively. The DNA fragments encoding mutants of hB-ind1 and p23 were prepared by the method of splicing by overlap extension (26) and introduced into pEF FLAGGs pGKpuro (28). The GRP78 promoter region was introduced between the KpnI and HindIII sites of pGL3-basic (Promega, Madison, WI) and designated pGRP78-luc. The reporter plasmid carrying a firefly luciferase gene under the control of the GR promoter (pGR-luc) was purchased from Panomics (Fremont, CA). The internal-control plasmid encoding a *Renilla* luciferase (pRL-TK) was purchased from Promega. The plasmid pFK-I₃₈₉ neo/NS3-3'/NK5.1 (47) was kindly provided by R. Bartenschlager. The plasmids used in this study were confirmed by sequencing them with an ABI Prism 3130 genetic analyzer (Applied Biosystems, Tokyo, Japan).

Cells and virus infection. All cell lines were cultured at 37°C under a humidified atmosphere and 5% CO₂. The human embryonic kidney 293T and hepatocellular carcinoma Huh7 cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma, St. Louis, MO) supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% fetal calf serum (FCS). The human hepatocellular carcinoma cell line Huh7.5.1 was kindly provided by F. Chisari (70) and was maintained in DMEM containing nonessential amino acids, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10% FCS. The Huh9-13 cell line, which is a Huh7 cell line harboring a subgenomic HCV RNA replicon (35), was maintained in DMEM containing 10% FCS, nonessential amino acids, and 1 mg/ml G418 (Nakalai Tesque, Kyoto, Japan). The hB-ind1 knockdown cell line Huh-KD and control cell line Huh-ctrl were described previously (56). Huh-KD cells were transfected with each of the expression plasmids encoding wild-type or mutant hB-ind1 and cultured for 1 week in the presence of 10 µg/ml of puromycin. The remaining cells were used for the experiments described below. The viral RNA of JFH1 was introduced into Huh7.5.1 cells according to the method of Wakita et al. (62) for preparation of the infectious HCV particles in cell culture.

Antibodies. The rabbit anti-hB-ind1 antibody was prepared as described previously (56). Mouse monoclonal antibodies to HCV NS5A, influenza virus hemagglutinin (HA) and FLAG tags, and β-actin were purchased from Austral Biologicals (San Ramon, CA), Covance (Richmond, CA), and Sigma, respectively. Mouse anti-protein disulfide isomerase (PDI) immunoglobulin G2a (IgG2a) was from Affinity Bioreagents (Golden, CO). Mouse anti-double-stranded RNA (dsRNA) IgG2a (J1 and K2) antibodies were from Biocenter Ltd. (Szirak, Hungary). Alexa Fluor 488 (AF488)-conjugated anti-mouse IgG1, AF647-conjugated anti-rabbit IgG, and AF594-conjugated anti-mouse IgG2a and IgG2b antibodies were from Invitrogen (San Diego, CA).

Transfection, immunoblotting, and immunoprecipitation. Transfection and immunoprecipitation analyses were carried out as described previously (25, 45). Immunoprecipitates boiled in loading buffer were subjected to 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The proteins were transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA) and were reacted with the appropriate antibodies. The immune complexes were visualized with Super Signal West Femto substrate (Pierce, Rockford, IL) and detected by an LAS-3000 image analyzer system (Fujifilm, Tokyo, Japan). The protein bands of GRP78 and β-actin were quantified by Multi Gauge software (Fujifilm), and the values of GRP78 expression were normalized with those of β-actin.

Quantitative reverse transcriptase PCR. HCV RNA was estimated by the method described previously (56). Total RNA was prepared from cells by using an RNeasy minikit (Qiagen, Tokyo, Japan). First-strand cDNA was synthesized using an RNA LA PCR in vitro cloning kit (Takara Bio Inc., Shiga, Japan) and random primers. Each cDNA was estimated with Platinum SYBR green qPCR SuperMix UDG (Invitrogen) according to the manufacturer's protocol. Fluorescent signals were analyzed with an ABI Prism 7000 (Applied Biosystems). The

internal ribosomal entry site regions of HCV and mRNAs of GAPDH (glyceraldehyde-3-phosphate dehydrogenase), GRP78, and growth arrest- and DNA damage-inducible gene 153 (GADD153) were amplified using the primer pairs 5'-GAGTGTCTGTCAGCCTCCA-3' and 5'-CACTCGCAAGCACCCTATC A-3', 5'-GAAGGTGAAGGTCGGAGTC-3' and 5'-GAAGGTGAAGGTCGG AGTC-3', 5'-CGCCAAGCGGCTC-3' and 5'-AACCACCTTGAACGGC AAGA-3', and 5'-AGCTGGAACCTGAGGAGAGA-3' and 5'-TGGATCAGT CTGAAAAGCA-3', respectively. The values of the HCV genome or each mRNA were normalized with those of GAPDH mRNA. Each PCR product was detected as a single band of the correct size on agarose gel electrophoresis (data not shown).

In vitro transcription and RNA transfection. The plasmid pFK-I₃₈₉ neo/NS3-3'/NK5.1 was linearized by treatment with ScaI and then transcribed in vitro using the MEGAscript T7 kit (Applied Biosystems) according to the manufacturer's protocol. The in vitro-transcribed RNA was electroporated into cells at 4 million cells/0.4 ml under conditions of 270 V and 960 µF using a Gene Pulser (Bio-Rad, Hercules, CA). The colony formation assay was carried out by a method described previously (45).

Indirect immunofluorescence assay. Cells cultured on glass slides were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) at room temperature for 30 min. After being washed twice with PBS, the cells were permeabilized for 20 min at room temperature with PBS containing 0.25% saponin and blocked with PBS containing 0.2% gelatin (gelatin-PBS) for 60 min at room temperature. The cells were incubated with gelatin-PBS containing rabbit anti-hB-ind1 antibody, mouse anti-NS5A IgG1, mouse anti-PDI IgG2a, mouse anti-FKBP8 IgG2b, or mouse anti-dsRNA IgG2a (J1 and K2) at 37°C for 60 min; washed three times with PBS containing 1% Tween 20; and incubated with gelatin-PBS containing AF488-conjugated anti-mouse IgG1 or AF647-conjugated anti-rabbit or AF594-conjugated anti-mouse IgG2a or IgG2b antibodies at 37°C for 60 min. Finally, the cells were washed three times with PBS containing 1% Tween 20 and observed with a FluoView FV1000 laser scanning confocal microscope (Olympus, Tokyo, Japan).

Correlative FM-EM. Correlative fluorescence microscopy-electron microscopy (FM-EM) allows individual cells to be examined both in an overview with FM and in a detailed subcellular-structure view with EM (51). The endogenous hB-ind1 and NS5A were stained and observed in the HCV replicon cells by the correlative FM-EM method as described previously (45).

Luciferase assay. Each plasmid was transfected into Huh7, Huh9-13, and interferon (IFN)-cured cells seeded in a 12-well plate, and the cells were treated with 1 µM dexamethasone (Sigma) for 12 h or with 17-dimethylamino-ethylamino-17-demethoxygeldanamycin (DMAG) (Sigma) for 6 h at 36 h posttransfection and lysed in 200 µl of passive lysis buffer (Promega). Luciferase activity was measured in 20-µl aliquots of the cell lysates using a Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity was standardized with that of *Renilla* luciferase cotransfected with the internal-control plasmid pRL-TK. The resulting values were expressed as the increase in relative light units (RLU).

Statistical analysis. Results were expressed as the mean ± standard deviation. The significance of differences in the means was determined by Student's *t* test.

RESULTS

The p23-like domain of hB-ind1 has cochaperone activity. Although we had previously reported that hB-ind1 regulates HCV RNA replication through interaction with NS5A and Hsp90, the molecular mechanisms underlying the regulation of HCV replication remained to be clarified. To gain more insights into the potential cochaperone activity of hB-ind1 in the Hsp90 chaperone system, we prepared expression plasmids encoding a wild-type p23 and three p23 mutants—one in which the FXXW motif was replaced with AXXA (p23AxxA), one in which the cochaperone domain of p23 was replaced with the p23-like domain of hB-ind1 (cp23), and one in which both substitutions were made (cp23AxxA) (Fig. 1A). HA-tagged Hsp90 was coexpressed with FLAG-tagged p23 or the FLAG-tagged p23 mutants in 293T cells (Fig. 1B). Hsp90 was coimmunoprecipitated with wild-type p23 and a cp23 mutant, but not with the p23AxxA or cp23AxxA mutants, indicating that the FXXW motif of hB-ind1, as is the case with that of p23




FIG. 1. Construction and characterization of p23 mutants. (A) Structures of hB-ind1, p23, and the three p23 mutants. hB-ind1 consists of a p23-like domain, an FXXW motif, a coiled-coil domain (CC), and a transmembrane domain (TM). p23 consists of a co-chaperone domain, an FXXW motif, and a chaperone domain (CD). The three p23 mutants, p23AxxA, cp23, and cp23AxxA, were constructed by replacing the FXXW motif with AXXA, the co-chaperone domain of p23 with the p23-like domain of hB-ind1, and both of the regions, respectively. (B) FLAG-tagged p23, p23AxxA, cp23, or cp23AxxA was coexpressed with HA-tagged Hsp90 in 293T cells and immunoprecipitated (IP) with anti-FLAG antibody. The immunoprecipitates were subjected to immunoblotting (IB). (C) The expression plasmid encoding FLAG-tagged p23, cp23, p23AxxA, or cp23AxxA was cotransfected with pGR-luc and pRL-TK plasmids into 293T cells and treated with 1 mM dexamethasone [Dex(+)] at 36 h posttransfection or untreated [Dex(-)], and the luciferase activities were determined at 12 h of incubation. The firefly luciferase activity was normalized with that of *Renilla* luciferase, and the GR-responsive promoter activity was indicated as the RLU. The error bars indicate standard deviations. The asterisks indicate significant differences ($P < 0.01$) versus the control value. The data shown are representative of three independent experiments.

(67), is also involved in binding to Hsp90. Hsp90 participates in the folding and stabilization of the ligand-binding domain of the glucocorticoid receptor (GR), together with p23 and other cofactors (49). p23 was shown to act not only in the activation (30), but also in the inhibition, of GR signaling (67). To examine whether hB-ind1 has the ability to work as a cochaperone in an Hsp90-dependent manner, each of the plasmids encoding p23 or the p23 mutants was cotransfected with a reporter plasmid carrying a firefly luciferase gene under the control of the GR promoter (pGR-luc), together with an internal-control plasmid (pRL-TK), and GR-mediated transcriptional activity was determined at 12 h after treatment with dexamethasone, a ligand of GR. Expression of the p23 or cp23 mutant, but not of the AXXA mutants, significantly inhibited GR-mediated transcription (Fig. 1C). These results indicate that the p23-like domain of hB-ind1 possesses cochaperone activity comparable to that of p23.

The p23-like domain of hB-ind1 is interchangeable with the p23 cochaperone domain during complex formation with NS5A, Hsp90, and FKBP8. Previous reports have suggested that HCV NS5A interacts with several host proteins, including FBL2 (63), vesicle-associated membrane protein-associated protein subtype A (VAP-A) (61), VAP-B (25), FKBP8 (45), and hB-ind1 (56), and that these interactions participate in the replication of HCV. We have shown that hB-ind1 interacts with NS5A and Hsp90 through the coiled-coil domain and the FXXW motif in the p23-like domain, respectively, and that coexpression of FKBP8 enhances the interaction of Hsp90 with hB-ind1 (56). To determine the effect of the mutation in the p23-like domain of hB-ind1 on interaction with Hsp90, NS5A, and FKBP8, we prepared an expression plasmid encoding wild-type hB-ind1 and three hB-ind1 mutants, one in which the p23-like domain was replaced with the co-chaperone domain of p23 (chB-ind1), one in which the FXXW motif was replaced with AXXA (hB-ind1AxxA), and one in which both replacements were made (chB-ind1AxxA) (Fig. 2A). The FLAG-tagged wild-type or mutant hB-ind1 was coexpressed with HA-tagged Hsp90 (Fig. 2B, left) or HA-tagged NS5A (Fig. 2B, right) in 293T cells and immunoprecipitated with anti-FLAG antibody. Hsp90 was coprecipitated with wild-type hB-ind1 and the chB-ind1 mutant, but not with the hB-ind1AxxA and chB-ind1AxxA mutants (Fig. 2B, left), confirming that the FXXW motif is crucial for the interaction with Hsp90. In contrast, NS5A was coprecipitated with each of the hB-ind1 proteins, suggesting that mutation in the p23-like domain of hB-ind1 has no effect on the binding of hB-ind1 to NS5A through the coiled-coil domain (Fig. 2B, right). To determine the effect of FKBP8 expression on the interaction between hB-ind1 and Hsp90, FLAG-tagged wild-type hB-ind1 or the chB-ind1 mutant was coexpressed with HA-tagged FKBP8 and/or Hsp90 in 293T cells and immunoprecipitated with anti-FLAG antibody. The amounts of Hsp90 coprecipitated with hB-ind1 or chB-ind1 were increased by coexpression of FKBP8 (Fig. 2C). To further examine the interaction of hB-ind1 with Hsp90 and NS5A at an endogenous expression level in Huh9-13 cells harboring an HCV subgenomic RNA replicon, lysates of the replicon cells were subjected to immunoprecipitation analysis. Endogenous Hsp90 and NS5A were specifically coimmunoprecipitated with endogenous hB-ind1 (Fig. 2D). These results suggest that the p23-like domain of hB-ind1 is inter-




FIG. 2. Construction and characterization of hB-ind1 mutants. (A) Structures of p23, hB-ind1, and the three hB-ind1 mutants. The three hB-ind1 mutants, hB-ind1AxxA, chB-ind1, and chB-ind1AxxA, were constructed by replacing the FXXW motif with AXXA, the p23-like domain of hB-ind1 with the co-chaperone domain of p23, and both of the regions, respectively. (B) FLAG-tagged hB-ind1, hB-ind1AxxA, chB-ind1, or chB-ind1AxxA was coexpressed with either HA-tagged Hsp90 (left) or NS5A (right) in 293T cells and immunoprecipitated (IP) with anti-FLAG antibody. The immunoprecipitates were subjected to immunoblotting (IB). (C) HA-tagged Hsp90 and HA-FKBP8 were expressed with FLAG-tagged hB-ind1 and chB-ind1 in various combinations in 293T cells and immunoprecipitated with anti-FLAG antibody, and the immunoprecipitates were detected by immunoblotting. (D) Endogenous hB-ind1 in Huh9-13 cells harboring subgenomic HCV replicon RNA was immunoprecipitated with anti-hB-ind1 rabbit IgG (lane 2). The cell lysate was mixed with normal rabbit IgG as a negative control (lane 1). The immunoprecipitates were analyzed by immunoblotting with an antibody to Hsp90, NS5A, or hB-ind1. The data shown are representative of three independent experiments.

changeable with the co-chaperone domain of p23 during complex formation with NS5A, Hsp90, and FKBP8.

Cochaperone activity in the p23-like domain of hB-ind1 is required for propagation of HCV. The p23-like domain of hB-ind1 has been suggested to be required for HCV propagation (56). However, the involvement of the co-chaperone activity of hB-ind1 in HCV propagation has not been examined. To assess the effect of co-chaperone activity in the p23-like domain of hB-ind1 on the RNA replication and particle production of HCV, each of the expression plasmids encoding the FLAG-tagged wild-type or mutant hB-ind1 carrying the silent mutations resistant to small interfering RNA was transfected into hB-ind1 knockdown (Huh-KD) cells and cultured for a week in the presence of puromycin. The expressions of FLAG-tagged hB-ind1 and the mutants in the Huh-KD cells were comparable to that of the endogenous hB-ind1 in the control (Huh-ctrl) cells transfected with an empty vector (Fig. 3A). Subgenomic HCV replicon RNA transcribed from pFK-1₃₈₉ neo/NS3-3'/NK5.1 was transfected into these cells and cultured for 4 weeks in the presence of G418. Although the number of colonies was reduced in the Huh-KD cells compared with the Huh-ctrl cells after transfection with an empty vector, as described previously (56), the colony numbers were recovered by the expression of the hB-ind1 or chB-ind1 mutant, but not by that of the hB-ind1AxxA or chB-ind1AxxA mutants (Fig. 3B). Similarly, intracellular HCV RNA and infectious viral titers in the culture supernatants of Huh-KD cells infected with JFH1 virus were partially recovered by the expression of the hB-ind1 or chB-ind1 mutant, but not by that of the hB-ind1AxxA or chB-ind1AxxA mutant (Fig. 3C). These results suggest that co-chaperone activity in the p23-like domain of hB-ind1 is required for HCV propagation and that the co-chaperone domain of p23 can substitute for the p23-like domain of hB-ind1.

hB-ind1 colocalizes with NS5A, FKBP8, and dsRNA on the membranous web. Our previous report revealed the interplay among hB-ind1, Hsp90, FKBP8, and NS5A and showed that these interactions play an important role in HCV replication (56). However, the subcellular localization of the endogenous hB-ind1 in the replicon cells and JFH1 virus-infected cells has not been precisely assessed. To determine the subcellular localization of hB-ind1 in the context of HCV replication, the expression of hB-ind1 and NS5A in the replicon cells and JFH1 virus-infected cells was examined by immunofluorescence analyses (Fig. 4A). Endogenous hB-ind1 was colocalized with the endoplasmic reticulum (ER)-marker PDI and NS5A as dot-like structures in the Huh9-13 replicon cells (Fig. 4A, top) and in cells infected with JFH1 virus (Fig. 4A, bottom), and these dot-like structures disappeared in concert with the loss of NS5A expression by treatment with IFN- α in the replicon cells and was not observed in the mock-infected Huh7.5.1 cells. Furthermore, FKBP8 (Fig. 4B, top) and dsRNA (Fig. 4B, bottom) were colocalized with hB-ind1 and NS5A in the dot-like structures in Huh9-13 replicon cells. These results indicate that HCV replicating RNA is localized with hB-ind1, FKBP8, and NS5A in the dot-like compartments. HCV RNA replication or expression of viral proteins leads to formation of the convoluted membranous structures designated the membranous web (14, 23). The large structures of the replication complexes in the replicon cells indicate membranous webs with




FIG. 3. Effects of the cochaperone activity of hB-ind1 on the propagation of HCV. (A) Huh-KD cells were transfected with either an empty vector or an expression plasmid encoding FLAG-tagged hB-ind1, hB-ind1AxxA, chB-ind1, or chB-ind1AxxA, which are resistant to small interfering RNA due to the introduction of silent mutations, and cultured for a week in the presence of 10 μ g/ml of puromycin. The surviving cells were used in the subsequent experiments. The endogenous and exogenous expression of hB-ind1 and the mutants was detected by immunoblotting. The control cell line (Huh-ctrl) or the Huh-KD cell line transfected with an empty vector (EV) was used as a control. (B) Huh-KD cells were transfected with the plasmids and

restricted motility (68). To further analyze the subcellular compartments, including hB-ind1 and NS5A, the same field of the Huh9-13 replicon cells was observed under FM and EM by using the correlative FM-EM technique (Fig. 5A, upper two rows). The large structures that included hB-ind1 and NS5A in the replicon cells were observed under FM and EM (white-boxed areas) and further magnified (black-boxed areas). Convoluted membranous structures that consisted of small vesicles and that were similar to the membranous web were observed. Another field of view yielded similar results (Fig. 5A, lower two rows). The membranous web resembling the convoluted structures was not observed in the Huh9-13 cells depleted of viral RNA by IFN treatment (Fig. 5B). Together, these results suggest that hB-ind1 interacts with NS5A on the membranous web in cells replicating HCV RNA.

Hsp90 is involved in the circumvention of the UPR during HCV replication. Hsp90 regulates the folding and stability of proteins in all eukaryotes (59), and inhibition of the chaperone pathway suppresses correct protein folding, which leads to induction of proteasome-mediated degradation of the unfolded proteins and the unfolded protein response (UPR). Our previous (46) and present studies (Fig. 4 and 5) showed that several cochaperone components are recruited in the membranous web, suggesting that the Hsp90 chaperone system participates in the replication complex to circumvent the induction of the UPR and to maintain the folding of the host and viral proteins in a replication-competent state. To determine the induction of the UPR by HCV replication, Huh9-13 replicon cells were transfected with a reporter plasmid carrying a firefly luciferase gene under the control of the GRP78 promoter, which is activated by the induction of the UPR, together with an internal-control plasmid. Although the GRP78 promoter activity was slightly enhanced in the Huh9-13 cells compared to that in the parental cells, a fourfold increase of GRP78 promoter activity in the replicon cells was observed after treatment with an Hsp90 inhibitor, DMAG, in contrast to the twofold increase in similarly treated parental Huh7 cells, and the activation of the GRP78 promoter was canceled by treatment with IFN- α despite DMAG treatment (Fig. 6A), suggesting that the Hsp90 chaperone system participates in the circumvention of the UPR induced by the replication of HCV RNA. In addition, activation of GRP78 at transcriptional and translational levels after treatment with DMAG was higher in the

then selected with puromycin. The resulting cells were further transfected with a replicon RNA transcribed from pFK-I₃₈₉ neo/NS3-3'/NK5.1, cultured for 4 weeks in the presence of 1 mg/ml of G418, and stained with crystal violet after fixation with 4% paraformaldehyde. The Huh-KD cell line transfected with an empty vector (EV) was used as a positive control. (C) The cells prepared as described above were infected with JFH1 virus and harvested at 3 days postinfection. The amount of intracellular HCV RNA was estimated by quantitative reverse transcriptase PCR and normalized with that of GAPDH mRNA. The values of HCV RNA are presented as percentages versus those of Huh-ctrl cells transfected with an empty vector. The culture supernatants were subjected to a focus-forming assay. Virus titers are presented as focus-forming units (FFU) per ml. The error bars indicate standard deviations. The asterisks indicate significant differences ($P < 0.01$) versus the value of the control. The data shown are representative of three independent experiments.




FIG. 4. Intracellular localization of hB-ind1 in replicon cells and infected cells. (A) Huh9-13 replicon cells with IFN- α or untreated and Huh7.5.1 cells infected with JFH1 virus or naïve cells were stained with antibodies against NS5A, hB-ind1, or PDI and examined by immunofluorescence assay. The boxed areas in the merged images are magnified and displayed on the right. The arrowheads indicate intracellular positions colocalized with NS5A, hB-ind1, and PDI. (B) Huh9-13 replicon cells were fixed, permeabilized, and stained with appropriate antibodies to NS5A, hB-ind1, and FKBP8 (top) or dsRNA (bottom). The boxed areas in the merged images are magnified and displayed on the right. The arrowheads indicate intracellular positions colocalized with NS5A, hB-ind, and FKBP8 or dsRNA. The images shown are representative of three independent experiments.

HCV replicon cells than in the parental cells or in cured cells, which were depleted of HCV RNA by treatment with IFN- α (Fig. 6B). Furthermore, DMAG treatment enhanced the transcription of the UPR marker protein GADD153 at a higher level in the replicon cells than in the parental Huh7 or the cured cells (Fig. 6C). These results suggest that the Hsp90-dependent chaperone system plays a crucial role in the folding of the host and viral proteins involved in HCV replication and in the regulation of UPR induction.

DISCUSSION

Studies of the relationship between Hsp90 and steroid receptors, such as GR, have revealed the activities of cochaperones (52, 67). Cochaperones, such as p23, appear to interact with and dissociate from Hsp90 and the client protein complex in a defined order. These cochaperones participate in the chaperone complex in a late step and promote the dissociation of the client proteins from Hsp90 to facilitate formation of the




FIG. 5. hB-ind1 interacts with NS5A in the membranous web. Huh9-13 replicon cells were stained with specific antibodies to hB-ind1 and NS5A. Identical fields of Huh9-13 (A) or the cured cells (B) were observed under EM by using the correlative FM-EM technique. The white-boxed areas indicate the colocalized areas of hB-ind1 with NS5A. Magnified views of the white-boxed areas are displayed in the third column from the left. The right column contains further-magnified images of each of the black-boxed areas. Another field of view is presented in the lower two rows.

chaperone complex in the next chaperone cycle (16–18). In this study, we have shown that hB-ind1 participates in HCV replication and that the p23-like domain of hB-ind1 possesses co-chaperone activity comparable to that of the cochaperone domain of p23, suggesting that hB-ind1 is involved in the recycling of the chaperone complex in the membranous web to maintain the function of the replication complex of HCV.

Previous studies have indicated that HCV proteins rear-

range the ER membrane into the small convoluted membranous vesicles that are collectively known as the membranous web, and these vesicles have been suggested to be the intracellular compartments in which HCV replication takes place (14, 23, 68). In the living replicon cells, two forms of replication complexes, small and large vesicles, are detected, both of which include the viral replication complexes (68). Large vesicles, corresponding to membranous webs, exhibit restricted motil-




FIG. 6. Effect of Hsp90 inhibitor on the induction of the UPR in HCV replicon cells. (A) Huh7 and Huh9-13 replicon cells were transfected with a reporter plasmid, pGRP78-luc, and an internal-control plasmid, pRL-TK. The transfected cells were treated with IFN- α (+IFN) from 6 to 36 h posttransfection or left untreated and then further incubated for 6 h in the presence or absence of 1 μ M DMAG. The resulting cells were harvested and subjected to a dual-luciferase assay. The firefly luciferase activity is indicated as the RLU (top) after standardization with that of *Renilla* luciferase. The enhancement of promoter activity by treatment with DMAG is presented as the increase (bottom). (B) Huh7 cells, Huh9-13 cells, and Huh9-13 cells cured by IFN- α treatment (Cured) were cultured for 6 h in the presence or absence of 1 μ M DMAG, and the amount of GRP78 mRNA was measured by real-time PCR. The value of the mRNA was normalized with the amount of GAPDH mRNA (upper left), and the transcriptional enhancement by treatment with DMAG is presented as the increase (lower left). The expression levels of GRP78 and β -actin in the cells were determined by immunoblotting (upper right) and are presented as the increase (lower right). (C) The amounts of GADD153 mRNA in Huh7 cells, Huh9-13 cells, and the cured cells cultured for 6 h in the presence or absence of 1 μ M DMAG were measured by real-time PCR. The values of the mRNA were normalized with the amount of GAPDH mRNA (top), and the transcriptional enhancement by treatment with DMAG is presented as the increase (bottom). The error bars indicate standard deviations. The asterisks indicate significant differences ($P < 0.01$) versus the control value. The data shown are representative of three independent experiments.

ity, while small vesicles show fast movement (68), and FM and EM have revealed that NS5A is colocalized with hB-ind1, as well as FKBP8 (45), in the membranous webs. hB-ind1 was first identified as a regulator of Rac1 that activates JNK and NF- κ B (11). Rac1 is a member of the Rho GTPase family and plays

crucial roles in cytoskeletal dynamics, membrane ruffling, and gene transcription through the effectors of the Rho GTPase family members. IQGAP1 and PAK1 are Rac1 effectors that bind to Rac proteins and are also involved in the replication of HCV (5, 7, 19, 31, 50). The tetratricopeptide repeat domain of immunophilin family members, such as FKBP8, has been shown to interact with Hsp90 (12, 45) and the GR-Hsp90 complex that leads to association with dynein for retrograde transport, along with microtubules (12). Hsp90 has been shown to play an important role in the interaction of transcriptase with genomic RNA of hepatitis B virus (27) and the nuclear transportation of the polymerase of influenza virus (40). Flock house virus also recruits Hsp90 in the polymerase synthesis in the early step of infection (9). Hsp90 may be involved in the regulation of the movement and arrangement of the HCV replication complexes through interaction with Rac1, hB-ind1, and FKBP8. Further investigation is needed to clarify the role of the Hsp90 chaperone system in the life cycle of HCV.

The surrounding membranes, including the membranous web, may protect the viral replication complex and RNA genome against digestion by the host proteases and nucleases (69). The replication complex is composed of viral nonstructural proteins and host proteins, including chaperone and co-chaperone proteins. HCV NS5A has been shown to interact with various host proteins, including cochaperones, such as FKBP8 and hB-ind1, and to recruit a chaperone, Hsp90, into the replication complex through interaction with these cochaperones. Recruitment of the chaperone complex into the replication complex is crucial for the correct folding of newly synthesized viral proteins to maintain the efficient replication of the viral genome. HCV replication has been shown to be improved by the adaptive mutations suppressing the phosphorylation status of NS5A in the replicon cells (3). Although suppression of the hyperphosphorylation of NS5A by treatment with kinase inhibitors improves the replication of the replicons that have no adaptive mutations (42), several kinase inhibitors have been shown to suppress the replication of the HCV replicon carrying the adaptive mutations (29), and phosphorylation of NS5A by casein kinase II was shown to improve virus production but not HCV RNA replication (57). Hsp90 is capable of directly modulating the activities of several kinases (37, 53, 54), and thus, it might be feasible that cochaperones, including hB-ind1 and FKBP8, participate in the propagation of HCV by regulating the phosphorylation status of NS5A in cooperation with Hsp90.

The host chaperone system regulates the quality of client proteins, and impairment of the chaperone activity induces accumulation of misfolded proteins and affects the natural cellular function and viability (20, 21, 33). In this study, DMAG treatment induced a higher level of UPR in HCV replicon cells than in parental and cured cells, indicating that the Hsp90 chaperone system participates in the maintenance of correct folding of the viral and host proteins in the replication complex in the membranous web and in the circumvention of the UPR induced by HCV replication. Treatment with geldanamycin or its derivatives has been shown to inhibit GRP94, which is the Hsp90 paralog located in the ER (10), and to disrupt the ER chaperone pathway, leading to the induction of ER-associated protein degradation, transcriptional attenuation, and eventually induction of apoptosis (34). ER chaperones, such as

GRP94, may also participate in the correct folding of the viral and host proteins in the replication complex for efficient replication of the HCV genome.

Geldanamycin and its derivatives have been reported to remarkably inhibit poliovirus replication *in vivo* without any emergence of drug-resistant escape mutants (22), suggesting that an inhibitor of the chaperone system may be a promising candidate for the treatment of viral infectious diseases with low risk of the emergence of drug-resistant viruses. In addition, Hsp90 inhibitors exhibit anticancer activities through the suppression of various cell signals essential for cancer growth and the enhancement of radiation sensitivity (2, 8, 13). In conclusion, our data indicate that hB-ind1 is included within the HCV replication complex and regulates HCV RNA replication through its own cochaperone activity. Hsp90 and cochaperones, including hB-ind1 and FKBP8, which are required for efficient HCV replication, should be ideal targets for the treatment of chronic hepatitis C with a low frequency of emergence of drug-resistant breakthrough viruses.

ACKNOWLEDGMENTS

We thank H. Murase for her secretarial work. We also thank R. Bartschlagler, T. Wakita, and F. V. Chisari for providing the plasmids and cell lines.

This work was supported in part by grants-in-aid from the Ministry of Health, Labor, and Welfare; the Ministry of Education, Culture, Sports, Science, and Technology; the Global Center of Excellence Program; the Foundation for Biomedical Research and Innovation; and the Naito Foundation.

REFERENCES

- Abe, T., Y. Kaname, I. Hamamoto, Y. Tsuda, X. Wen, S. Tagawa, K. Morishii, O. Takeuchi, T. Kawai, T. Kanto, N. Hayashi, S. Akira, and Y. Matsuura. 2007. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. *J. Virol.* **81**:8953–8966.
- Bisht, K. S., C. M. Bradbury, D. Mattson, A. Kaushal, A. Sowers, S. Markovina, K. L. Ortiz, L. K. Sieck, J. S. Isaacs, M. W. Brechbiel, J. B. Mitchell, L. M. Neckers, and D. Gius. 2003. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the *in vitro* and *in vivo* radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. *Cancer Res.* **63**:8984–8995.
- Blight, K. J., A. A. Kolykhalov, and C. M. Rice. 2000. Efficient initiation of HCV RNA replication in cell culture. *Science* **290**:1972–1974.
- Bohen, S. P., A. Kralli, and K. R. Yamamoto. 1995. Hold 'em and fold 'em: chaperones and signal transduction. *Science* **268**:1303–1304.
- Bost, A. G., D. Venable, L. Liu, and B. A. Heinz. 2003. Cytoskeletal requirements for hepatitis C virus (HCV) RNA synthesis in the HCV replicon cell culture system. *J. Virol.* **77**:4401–4408.
- Brown, G., H. W. Rixon, J. Steel, T. P. McDonald, A. R. Pitt, S. Graham, and R. J. Sugrue. 2005. Evidence for an association between heat shock protein 70 and the respiratory syncytial virus polymerase complex within lipid-raft membranes during virus infection. *Virology* **338**:69–80.
- Bryan, B. A., D. Li, X. Wu, and M. Liu. 2005. The Rho family of small GTPases: crucial regulators of skeletal myogenesis. *Cell Mol. Life Sci.* **62**:1547–1555.
- Calderwood, S. K., M. A. Khaleque, D. B. Sawyer, and D. R. Ciocca. 2006. Heat shock proteins in cancer: chaperones of tumorigenesis. *Trends Biochem. Sci.* **31**:164–172.
- Castorena, K. M., S. A. Weeks, K. A. Stapleford, A. M. Cadwallader, and D. J. Miller. 2007. A functional heat shock protein 90 chaperone is essential for efficient flock house virus RNA polymerase synthesis in *Drosophila* cells. *J. Virol.* **81**:8412–8420.
- Chavany, C., E. Mimnaugh, P. Miller, R. Bitton, P. Nguyen, J. Trepel, L. Whitesell, R. Schnur, J. Moyer, and L. Neckers. 1996. p185erbB2 binds to GRP94 *in vivo*. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2. *J. Biol. Chem.* **271**:4974–4977.
- Courvilleau, D., E. Chastre, M. Sabbah, G. Redeuilh, A. Afifi, and J. Mester. 2000. B-ind1, a novel mediator of Rac1 signaling cloned from sodium butyrate-treated fibroblasts. *J. Biol. Chem.* **275**:17344–17348.
- Davies, T. H., Y. M. Ning, and E. R. Sanchez. 2002. A new first step in activation of steroid receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. *J. Biol. Chem.* **277**:4597–4600.
- Didelot, C., D. Lanneau, M. Brunet, A. L. Joly, A. De Thonel, G. Chiosis, and C. Garrido. 2007. Anti-cancer therapeutic approaches based on intracellular and extracellular heat shock proteins. *Curr. Med. Chem.* **14**:2839–2847.
- Egger, D., B. Wolk, R. Gosert, L. Bianchi, H. E. Blum, D. Moradpour, and K. Bienz. 2002. Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. *J. Virol.* **76**:5974–5984.
- Evans, M. J., C. M. Rice, and S. P. Goff. 2004. Genetic interactions between hepatitis C virus replicons. *J. Virol.* **78**:12085–12089.
- Freeman, B. C., S. J. Felts, D. O. Toft, and K. R. Yamamoto. 2000. The p23 molecular chaperones act at a late step in intracellular receptor action to differentially affect ligand efficacies. *Genes Dev.* **14**:422–434.
- Freeman, B. C., and K. R. Yamamoto. 2002. Disassembly of transcriptional regulatory complexes by molecular chaperones. *Science* **296**:2232–2235.
- Frydman, J., and J. Hohfeld. 1997. Chaperones get in touch: the Hip-Hop connection. *Trends Biochem. Sci.* **22**:87–92.
- Fukata, M., M. Nakagawa, and K. Kaibuchi. 2003. Roles of Rho-family GTPases in cell polarisation and directional migration. *Curr. Opin. Cell Biol.* **15**:590–597.
- Garrido, C., M. Brunet, C. Didelot, Y. Zermati, E. Schmitt, and G. Kroemer. 2006. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. *Cell Cycle* **5**:2592–2601.
- Garrido, C., S. Gurbuxani, L. Ravagnan, and G. Kroemer. 2001. Heat shock proteins: endogenous modulators of apoptotic cell death. *Biochem. Biophys. Res. Commun.* **286**:433–442.
- Geller, R., M. Vignuzzi, R. Andino, and J. Frydman. 2007. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. *Genes Dev.* **21**:195–205.
- Gosert, R., D. Egger, V. Lohmann, R. Bartschlagler, H. E. Blum, K. Bienz, and D. Moradpour. 2003. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. *J. Virol.* **77**:5487–5492.
- Grakoui, A., D. W. McCourt, C. Wychowski, S. M. Feinstone, and C. M. Rice. 1993. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. *J. Virol.* **67**:2832–2843.
- Hamamoto, I., Y. Nishimura, T. Okamoto, H. Aizaki, M. Liu, Y. Mori, T. Abe, T. Suzuki, M. M. Lai, T. Miyamura, K. Moriishi, and Y. Matsuura. 2005. Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. *J. Virol.* **79**:13473–13482.
- Ho, S. N., H. D. Hunt, R. M. Horton, J. K. Pullen, and L. R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Gene* **77**:51–59.
- Hu, J., D. Flores, D. Toft, X. Wang, and D. Nguyen. 2004. Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function. *J. Virol.* **78**:13122–13131.
- Huang, D. C., S. Cory, and A. Strasser. 1997. Bcl-2, Bcl-XL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. *Oncogene* **14**:405–414.
- Huang, Y., K. Staschke, R. De Francesco, and S. L. Tan. 2007. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? *Virology* **364**:1–9.
- Hutchison, K. A., L. F. Stancato, J. K. Owens-Grillo, J. L. Johnson, P. Krishna, D. O. Toft, and W. B. Pratt. 1995. The 23-kDa acidic protein in reticulocyte lysate is the weakly bound component of the hsp foldosome that is required for assembly of the glucocorticoid receptor into a functional heterocomplex with hsp90. *J. Biol. Chem.* **270**:18841–18847.
- Ishida, H., K. Li, M. Yi, and S. M. Lemon. 2007. p21-activated kinase 1 is activated through the mammalian target of rapamycin/p70 S6 kinase pathway and regulates the replication of hepatitis C virus in human hepatoma cells. *J. Biol. Chem.* **282**:11836–11848.
- Kampmueller, K. M., and D. J. Miller. 2005. The cellular chaperone heat shock protein 90 facilitates Flock House virus RNA replication in *Drosophila* cells. *J. Virol.* **79**:6827–6837.
- Kim, H. P., D. Morse, and A. M. Choi. 2006. Heat-shock proteins: new keys to the development of cytoprotective therapies. *Exp. Opin. Ther. Targets* **10**:759–769.
- Lai, E., T. Teodoro, and A. Volchuk. 2007. Endoplasmic reticulum stress: signaling the unfolded protein response. *Physiology* **22**:193–201.
- Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartschlagler. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* **285**:110–113.
- McLauchlan, J., M. K. Lemberg, G. Hope, and B. Martoglio. 2002. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. *EMBO J.* **21**:3980–3988.
- Miyata, Y., and I. Yahara. 1992. The 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activity. *J. Biol. Chem.* **267**:7042–7047.
- Momose, F., T. Naito, K. Yano, S. Sugimoto, Y. Morikawa, and K. Nagata.

2002. Identification of Hsp90 as a stimulatory host factor involved in influenza virus RNA synthesis. *J. Biol. Chem.* 277:45306–45314.
39. Moradpour, D., F. Penin, and C. M. Rice. 2007. Replication of hepatitis C virus. *Nat. Rev. Microbiol.* 5:453–463.
 40. Naito, T., F. Momose, A. Kawaguchi, and K. Nagata. 2007. Involvement of Hsp90 in assembly and nuclear import of influenza virus RNA polymerase subunits. *J. Virol.* 81:1339–1349.
 41. Neckers, L. 2002. Hsp90 inhibitors as novel cancer chemotherapeutic agents. *Trends Mol. Med.* 8:S55–S61.
 42. Neddermann, P., M. Quintavalle, C. Di Pietro, A. Clementi, M. Cerretani, S. Altamura, L. Bartholomew, and R. De Francesco. 2004. Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture. *J. Virol.* 78:13306–13314.
 43. Okamoto, K., Y. Mori, Y. Komoda, T. Okamoto, M. Okochi, M. Takeda, T. Suzuki, K. Moriishi, and Y. Matsuura. 2008. Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation. *J. Virol.* 82:8349–8361.
 44. Okamoto, K., K. Moriishi, T. Miyamura, and Y. Matsuura. 2004. Intramembrane proteolysis and endoplasmic reticulum retention of hepatitis C virus core protein. *J. Virol.* 78:6370–6380.
 45. Okamoto, T., Y. Nishimura, T. Ichimura, K. Suzuki, T. Miyamura, T. Suzuki, K. Moriishi, and Y. Matsuura. 2006. Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. *EMBO J.* 25:5015–5025.
 46. Okamoto, T., H. Omori, Y. Kaname, T. Abe, Y. Nishimura, T. Suzuki, T. Miyamura, T. Yoshimori, K. Moriishi, and Y. Matsuura. 2008. A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. *J. Virol.* 82:3480–3489.
 47. Pietschmann, T., V. Lohmann, A. Kaul, N. Krieger, G. Rinck, G. Rutter, D. Strand, and R. Bartenschlager. 2002. Persistent and transient replication of full-length hepatitis C virus genomes in cell culture. *J. Virol.* 76:4008–4021.
 48. Prapapanich, V., S. Chen, E. J. Toran, R. A. Rimerman, and D. F. Smith. 1996. Mutational analysis of the hsp70-interacting protein Hip. *Mol. Cell Biol.* 16:6200–6207.
 49. Pratt, W. B., and D. O. Toff. 1997. Steroid receptor interactions with heat shock protein and immunophilin chaperones. *Endocr. Rev.* 18:306–360.
 50. Ridley, A. J., H. F. Paterson, C. L. Johnston, D. Diekmann, and A. Hall. 1992. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. *Cell* 70:401–410.
 51. Rieder, C. L., and S. S. Bowser. 1985. Correlative immunofluorescence and electron microscopy on the same section of epon-embedded material. *J. Histochem. Cytochem.* 33:165–171.
 52. Sanchez, E. R., D. O. Toff, M. J. Schlesinger, and W. B. Pratt. 1985. Evidence that the 90-kDa phosphoprotein associated with the untransformed L-cell glucocorticoid receptor is a murine heat shock protein. *J. Biol. Chem.* 260:12398–12401.
 53. Sato, S., N. Fujita, and T. Tsuruo. 2000. Modulation of Akt kinase activity by binding to Hsp90. *Proc. Natl. Acad. Sci. USA* 97:10832–10837.
 54. Stancato, L. F., A. M. Silverstein, J. K. Owens-Grillo, Y. H. Chow, R. Jove, and W. B. Pratt. 1997. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. *J. Biol. Chem.* 272:4013–4020.
 55. Stravopodis, D. J., L. H. Margaritis, and G. E. Voutsinas. 2007. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. *Curr. Med. Chem.* 14:3122–3138.
 56. Taguwa, S., T. Okamoto, T. Abe, Y. Mori, T. Suzuki, K. Moriishi, and Y. Matsuura. 2008. Human butyrate-induced transcript 1 interacts with hepatitis C virus NS5A and regulates viral replication. *J. Virol.* 82:2631–2641.
 57. Tellinghuisen, T. L., K. L. Foss, and J. Treadaway. 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. *PLoS Pathog.* 4:e1000032.
 58. Tellinghuisen, T. L., J. Marcotrigiano, and C. M. Rice. 2005. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. *Nature* 435:374–379.
 59. Terasawa, K., M. Minami, and Y. Minami. 2005. Constantly updated knowledge of Hsp90. *J. Biochem.* 137:443–447.
 60. Tomei, L., C. Faila, E. Santolini, R. De Francesco, and N. La Monica. 1993. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. *J. Virol.* 67:4017–4026.
 61. Tu, H., L. Gao, S. T. Shi, D. R. Taylor, T. Yang, A. K. Mircheff, Y. Wen, A. E. Gorbalenya, S. B. Hwang, and M. M. Lai. 1999. Hepatitis C virus RNA polymerase and NS5A complex with a SNARE-like protein. *Virology* 263:30–41.
 62. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* 11:791–796.
 63. Wang, C., M. Gale, Jr., B. C. Keller, H. Huang, M. S. Brown, J. L. Goldstein, and J. Ye. 2005. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. *Mol. Cell* 18:425–434.
 64. Wasley, A., and M. J. Alter. 2000. Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin. Liver Dis.* 20:1–16.
 65. Watashi, K., N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyanari, and K. Shimotohno. 2005. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. *Mol. Cell* 19:111–122.
 66. Whitesell, L., and S. L. Lindquist. 2005. HSP90 and the chaperoning of cancer. *Nat. Rev. Cancer.* 5:761–772.
 67. Wochnik, G. M., J. C. Young, U. Schmidt, F. Holsboer, F. U. Hartl, and T. Rein. 2004. Inhibition of GR-mediated transcription by p23 requires interaction with Hsp90. *FEBS Lett.* 560:35–38.
 68. Wolk, B., B. Buchele, D. Moradpour, and C. M. Rice. 2008. A dynamic view of hepatitis C virus replication complexes. *J. Virol.* 82:10519–10531.
 69. Yang, G., D. C. Pevear, M. S. Collett, S. Chunduru, D. C. Young, C. Benetatos, and R. Jordan. 2004. Newly synthesized hepatitis C virus replicon RNA is protected from nuclease activity by a protease-sensitive factor(s). *J. Virol.* 78:10202–10205.
 70. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. *Proc. Natl. Acad. Sci. USA* 102:9294–9299.

Human VAP-C Negatively Regulates Hepatitis C Virus Propagation[∇]

Hiroshi Kukihara,¹ Kohji Moriishi,¹ Shuhei Taguwa,¹ Hideki Tani,¹ Takayuki Abe,¹
Yoshio Mori,¹ Tetsuro Suzuki,² Takasuke Fukuhara,^{1,3} Akinobu Taketomi,³
Yoshihiko Maehara,³ and Yoshiharu Matsuura^{1*}

Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Osaka,¹ Department of Virology II, National Institute of Infectious Diseases, Tokyo,² and Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka,³ Japan

Received 3 May 2009/Accepted 2 June 2009

Human vesicle-associated membrane protein-associated protein (VAP) subtype A (VAP-A) and subtype B (VAP-B) are involved in the regulation of membrane trafficking, lipid transport and metabolism, and the unfolded protein response. VAP-A and VAP-B consist of the major sperm protein (MSP) domain, the coiled-coil motif, and the C-terminal transmembrane anchor and form homo- and heterodimers through the transmembrane domain. VAP-A and VAP-B interact with NS5B and NS5A of hepatitis C virus (HCV) through the MSP domain and the coiled-coil motif, respectively, and participate in the replication of HCV. VAP-C is a splicing variant of VAP-B consisting of the N-terminal half of the MSP domain of VAP-B followed by the subtype-specific frameshift sequences, and its biological function has not been well characterized. In this study, we have examined the biological functions of VAP-C in the propagation of HCV. VAP-C interacted with NS5B but not with VAP-A, VAP-B, or NS5A in immunoprecipitation analyses, and the expression of VAP-C inhibited the interaction of NS5B with VAP-A or VAP-B. Overexpression of VAP-C impaired the RNA replication of the HCV replicon and the propagation of the HCV JFH1 strain, whereas overexpression of VAP-A and VAP-B enhanced the replication. Furthermore, the expression of VAP-C was observed in various tissues, whereas it was barely detected in the liver. These results suggest that VAP-C acts as a negative regulator of HCV propagation and that the expression of VAP-C may participate in the determination of tissue tropism of HCV propagation.

Hepatitis C virus (HCV) is a major causative agent of chronic liver disease and thus a major public health problem, infecting at least 3% of the world population (47). HCV infection proceeds to the persistent stage in approximately 80% of patients, leading to the development of cirrhosis in 20% to 50% of patients, of whom approximately 5% eventually develop hepatocellular carcinoma (12). HCV encompasses a single-stranded positive-sense RNA genome of approximately 9.6 kb, which encodes a large precursor polyprotein comprising approximately 3,000 amino acids (26). The structural proteins are cleaved from the N-terminal one-fourth of the polyprotein by the host signal peptidase and signal peptide peptidase (23, 32, 33), resulting in the maturation of the capsid protein, two envelope proteins and viroporin p7. The NS2 protease cleaves after the carboxyl terminus, and then NS3 cleaves the appropriate downstream positions to produce NS4A, NS4B, NS5A, and NS5B (8, 42), all of which form the replication complex along with several host proteins (5, 21). NS5B is the RNA-dependent RNA polymerase, which is a main enzymatic component of the replication complex of HCV (3), while NS5A is a membrane-anchored zinc-binding phosphoprotein that appears to possess diverse functions, including the suppression of host defense and the regulation of the virus's replication (1, 4, 6, 41), although its biological function remains unclear.

The NS5A protein has been shown to interact with several host proteins, including vesicle-associated membrane protein (VAMP)-associated protein (VAP) subtype A (VAP-A) (44) and subtype B (VAP-B) (9), FKBP8 (34), MyD88 (1), FBL2 (46), human butyrate-induced transcript 1 (hB-ind1) (40), and so on (25). VAP-A and VAP-B also bind to NS5B, although it remains unclear whether these interactions modulate HCV replication positively or negatively (9, 44). VAP-A and VAP-B have been shown to associate with the cytoplasmic face of the endoplasmic reticulum (ER) and the Golgi apparatus (38) and to consist of the major sperm protein (MSP) domain, the coiled-coil domain, and the transmembrane (TM) region, in that order (30, 39), as shown in Fig. 1A. VAP was originally reported as a protein binding to VAMP, which is a synaptic vesicle SNARE protein required for synaptic-vesicle fusion in the nematode *Aplysia californica*, and was designated the 33-kDa VAMP-associated protein, VAP-33 (39). Two mammalian homologues, VAP-A and VAP-B, were subsequently identified (30, 38). The transcription of VAP-A and VAP-B is ubiquitously detected in mammalian organs, including the heart, placenta, lung, liver, skeletal muscle, and pancreas (30), suggesting that VAP family proteins are involved in diverse cellular functions other than neurotransmitter release (30, 38, 49). Several VAP-interacting proteins share the FFAT motif (two phenylalanines in an acidic tract), which has the consensus amino acid sequence EFFDAXE, as determined by a comparison among oxysterol binding proteins (OSBPs), OSBP-related proteins (ORPs) (20), and the ceramide transport protein CERT (10, 19), contributing to the regulation of fatty acid metabolism. The interaction of VAP family proteins with

* Corresponding author. Mailing address: Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, 3-1, Yamadaoka, Suita, Osaka 565-0871, Japan. Phone: 81-6-6879-8340. Fax: 81-6-6879-8269. E-mail: matsuura@biken.osaka-u.ac.jp.

[∇] Published ahead of print on 10 June 2009.




FIG. 1. VAP-C interacts with neither VAP-A nor VAP-B. (A) Structures of VAP family proteins. The MSP domain, the coiled-coil domain, and the TM region are indicated as MSP, CC, and TM, respectively. (B) Interaction among VAP family proteins. The expression plasmids encoding VAP proteins or empty vector (1 μ g each) were transfected into 293T cells, FLAG-tagged VAP proteins coexpressed with EE-tagged VAP-A or VAP-B were immunoprecipitated (IP) with anti-FLAG antibody, and the resulting precipitates were examined by immunoblotting using anti-FLAG or anti-EE antibody. One percent of the volume of the lysate was used as an input control. The data in each panel are representative of the results of three independent experiments. +, present.

other host proteins, including VAMP and tubulin, is independent of the FFAT motif (16, 36, 38, 50). The third subtype of VAP is VAP-C, which is an alternative spliced isoform of VAP-B, consisting of the N-terminal half of the MSP domain and the subtype-specific 29 amino acids (Fig. 1A). However, its tissue distribution and physiological function remain largely unknown.

Glutathione *S*-transferase pulldown and immunoprecipitation analyses revealed that both VAP-A and VAP-B interact with NSSB and NS5A through the MSP domain and the coiled-coil domain, respectively (9, 44), and the MSP domains of VAP-A and VAP-B exhibit 82.3% homology. Although VAP-C possesses the N-terminal-half region of the MSP domain of VAP-B, the biological significance of VAP-C in the propagation of HCV has not yet been clarified. In this study, we examined the expression of VAP-C in human tissues and the effects of VAP-C expression on the RNA replication, translation, and particle formation of HCV.

MATERIALS AND METHODS

Cell lines. Cells of the human hepatoma cell line Huh-7, cell line Huh7OK1, and embryonic kidney cell line 293T were maintained in Dulbecco's modified Eagle's medium (DMEM) (Sigma, St. Louis, MO) containing 10% fetal calf

serum (FCS) and nonessential amino acids (NEAA), while Huh 9-13 cells, which possess a subgenomic HCV RNA replicon of genotype 1b (21), were cultured in DMEM supplemented with 10% FCS, NEAA, and 1 mg/ml G418. The Huh7OK1 cell line exhibits the highest efficiency of propagation of strain JFH1 virus, as described previously (35). All cell lines were cultured at 37°C in a humidified atmosphere with 5% CO₂.

Antibodies. Chicken anti-human VAP-B antibody was described previously (9). Rabbit anti-human VAP-C antibody was prepared by immunization using synthetic peptides of the amino acid residues from 86 to 98, QPHFSISPNW EGR, which region does not share the homology to VAP-A and VAP-B. The mouse monoclonal antibody to human VAP-A was purchased from BD Pharmingen (San Diego, CA). Mouse monoclonal antibodies to influenza virus hemagglutinin (HA) and the GluGlu (EE) tag were from Covance (Richmond, CA). Mouse and rabbit anti-FLAG antibodies and mouse anti- β -actin monoclonal antibody were from Sigma. Rabbit polyclonal antibody to NS5A was prepared as described previously (34). Mouse anti-NS5A monoclonal antibody was from Austral Biologicals (San Ramon, CA).

Plasmids. A cDNA clone encoding NS5A was amplified from HCV genotype 1b strain J1 (9) (GenBank database accession number D89815) by PCR, using *Pfu* turbo DNA polymerase (Stratagene, La Jolla, CA). The fragments were then cloned into the appropriate sites in pEF-FLAG pGBK puro (13), as described previously (9). A DNA fragment encoding VAP-C was amplified from cDNA of hepatoma cell line Huh-7 and was introduced into pEF-FLAG pGBK puro. Pro⁵⁶-to-Ser (P56S) mutants of VAPs were generated by site-directed mutagen-

esis (11). All PCR products were confirmed by sequencing with an ABI Prism 3130 genetic analyzer (Applied Biosystems, Tokyo, Japan).

Transfection, immunoblotting, and immunoprecipitation. Cells were seeded onto a six-well tissue culture plate 24 h before transfection. The plasmids were transfected into cells by liposome-mediated transfection using TransIT LT1 (Mirus Bio, Madison, WI). These transfected cells were harvested at 36 h posttransfection, washed three times with 1 ml of ice-cold phosphate-buffered saline (PBS), and suspended in 0.2 ml lysis buffer (20 mM Tris-HCl, pH 7.4, containing 135 mM NaCl and 1% Triton X-100) supplemented with protease inhibitor cocktail (Roche, Indianapolis, IN). The cell lysates were sonicated at 4°C for 5 min, incubated for 30 min at 4°C, and centrifuged at 15,000 rpm for 30 min at 4°C. The supernatant was subjected to immunoprecipitation analyses as described previously (27). The immunoprecipitated proteins were boiled in 30 μ l of loading buffer and then subjected to sodium dodecyl sulfate–12.5% polyacrylamide gel electrophoresis. The proteins were transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA) and then reacted with primary antibody and secondary horseradish peroxidase-conjugated antibody. The immunocomplexes were visualized with Super Signal West Femto substrate (Pierce, Rockford, IL) and detected by using an LAS-3000 image analyzer (Fujifilm, Tokyo, Japan). The distribution of VAPs in human organs was determined by using premade human tissue lysates (Protein medleys; Clontech), which are aliquots of various organ lysates prepared from samples from several people, and liver tissues obtained during surgery after approval of the ethical committee of Kyushu University Graduate School of Medicine.

Real-time PCR. The HCV genomic RNA was determined by the method described previously (40). Total RNA was prepared from cells by using an RNeasy mini kit (Qiagen, Tokyo, Japan). First-strand cDNA was synthesized using an RNA LA PCR kit (Takara Bio, Inc., Shiga, Japan) and random primers. Expression of the appropriate gene was estimated by using platinum SYBR green quantitative PCR SuperMix UDG (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. Fluorescent signals were estimated by using an ABI Prism 7000 system (Applied Biosystems). The 5' untranslated region of HCV and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were amplified using primer pairs described previously (40). The amount of HCV genomic RNA was normalized with that of GAPDH mRNA.

Focus-forming assay. The viral RNA of the JFH1 strain was introduced into the Huh7OK1 cell line according to the method of Zhong et al. (51). The culture supernatant was collected at 7 days posttransfection and used as the infectious HCV particles. Huh7OK1 cells in DMEM containing 10% FCS were seeded at 5×10^4 cells per well into a 24-well plate 12 h before infection. The cells were infected with the JFH1 strain at a multiplicity of infection (MOI) of 0.05 and incubated at 37°C for 2 h. The medium was replaced with fresh DMEM containing 10% FCS and NEAA at 2 h postinfection. The cells were fixed with 4% paraformaldehyde at 96 h postinfection and permeabilized with PBS containing 0.2% Triton X-100. These fixed and permeabilized cells were stained with the anti-NS5A mouse monoclonal antibody and Alexa Fluor (AF) 488-conjugated antibody to mouse immunoglobulin G (Molecular Probes, Eugene, OR). Clusters of infected cells stained with the NS5A antibody were derived from a single infectious focus, and virus titers were represented as focus-forming units/ml.

Quantification of the HCV core protein by ELISA. The HCV core protein was quantified by using an Ortho HCV antigen enzyme-linked immunosorbent assay (ELISA) test (Ortho Clinical Diagnostics, Tokyo, Japan) according to the manufacturer's instructions. To determine the intracellular expression of core protein, Huh7OK1 cells were infected with the infectious HCV particles described above, lysed with the lysis buffer on ice, and applied to the ELISA after 100- to 10,000-fold dilution with PBS. Total protein was quantified by using a Micro BCA protein assay reagent kit (Pierce). The intracellular and extracellular levels of expression of the core protein were normalized by the total amount of protein.

Effect of the VAP expression on the cap-independent translational activity of the viral IRES. The cDNA fragment encoding a firefly luciferase was excised from a pGL3 basic plasmid (Promega, Madison, WI) and introduced into the downstream region of the *Renilla* luciferase gene of pRL-CMV (cytomegalovirus) (Promega). Then, the cDNA fragments encoding the internal ribosome entry site (IRES) of the HCV strains Con1 and JFH1 were introduced between the *Renilla* and firefly luciferase genes, and the resulting plasmids were designated pRL-CMV-HCVCon1 and pRL-CMV-HCVJFH1, respectively (see Fig. 4A). The IRES region of HCV was replaced with that of poliovirus (PV) or encephalomyocarditis virus (EMCV), and the plasmids designated pRL-CMV-PV and pRL-CMV-EMCV, respectively (see Fig. 4B). Each reporter plasmid was introduced into Huh7OK1 cells that had been transfected with the expression plasmid encoding FLAG-green fluorescent protein (GFP), FLAG-VAP-A, FLAG-VAP-B, or FLAG-VAP-C 24 h previously, and cells were harvested at 48 h posttransfection. Luciferase activities in cells were measured by

using a dual-luciferase reporter assay system (Promega). The activity of firefly luciferase was normalized with that of *Renilla* luciferase and represented as relative luciferase activity (RLU).

Indirect immunofluorescence assay. The Huh 9-13 cells were cultured on glass slides and transfected with the expression plasmids encoding FLAG-tagged VAPs, P56S VAP mutants, or empty vector. The resulting cells were fixed at 72 h posttransfection with 4% paraformaldehyde in PBS at room temperature for 30 min. After being washed twice with PBS, cells were permeabilized for 20 min at room temperature with PBS containing 0.25% saponin and blocked with PBS containing 1% bovine serum albumin (BSA-PBS) for 60 min at room temperature. The cells were then incubated with BSA-PBS containing rabbit anti-FLAG and mouse anti-NS5A antibodies at 37°C for 60 min, washed three times with PBS containing 1% Tween 20 (PBS-T), and incubated with BSA-PBS containing AF 488-conjugated goat anti-rabbit immunoglobulin G and AF 594-conjugated goat anti-mouse antibodies at 37°C for 60 min. Finally, the cells were washed three times with PBS-T and observed with a FluoView FV1000 laser-scanning confocal microscope (Olympus, Tokyo, Japan).

RESULTS

VAP-C interacts with neither VAP-A nor VAP-B. The length of VAP-A was originally reported to be 242 amino acids but was recently corrected to 249 amino acids in the GenBank database due to the detection of 7 extra amino acids in the N terminus (Fig. 1A). VAP-C is a splicing variant of VAP-B that shares the N-terminal half of the MSP domain with VAP-B but lacks the coiled-coil motif and TM region (Fig. 1A). The region spanning residues 71 to 99 of VAP-C exhibits no homology to VAP-A and VAP-B, due to the frameshift. VAP-A and VAP-B form homo- or heterodimers via their TM domains, which is required for HCV replication (9, 44). To examine whether VAP-C is capable of interacting with VAP-A and VAP-B, FLAG-tagged VAP-A, -B, or -C was coexpressed with EE-tagged VAP-A or -B in 293T cells and was immunoprecipitated with the anti-FLAG antibody. Although EE-tagged VAP-A and VAP-B were coprecipitated with FLAG-tagged VAP-B and VAP-A, as reported previously, FLAG-VAP-C was precipitated with neither EE-VAP-A nor EE-VAP-B (Fig. 1B). These results indicate that VAP-C does not interact with VAP-A and VAP-B.

VAP-C binds to NS5B and interrupts the interaction of VAP-A and VAP-B with NS5B. VAP-A and VAP-B were identified as NS5A-binding proteins by yeast two-hybrid screening (9, 44). The coiled-coil domains of VAP-A and VAP-B were involved in the binding to NS5A, contributing to the efficiency of HCV replication (9, 44). However, VAP-C does not have the coiled-coil domain (Fig. 1A) and, therefore, VAP-C was expected not to interact with NS5A. To examine whether or not interaction between VAP-C and NS5A actually occurred, HA-tagged NS5A was coexpressed with FLAG-tagged VAP-A, -B, or -C in 293T cells and was immunoprecipitated with anti-HA antibody (Fig. 2). The results showed that the expression level of FLAG-VAP-C in the transfected cells was comparable to that of FLAG-VAP-A or FLAG-VAP-B (Fig. 2A, left). Although FLAG-tagged VAP-A and VAP-B were coprecipitated with HA-NS5A, no precipitation of FLAG-VAP-C with NS5A was detected (Fig. 2A, right), indicating that VAP-C does not interact with NS5A.

The RNA-dependent RNA polymerase NS5B was shown to interact with VAP-A through the MSP domain (44). The region spanning residues 1 to 70 of VAP-C is the same as the N-terminal-half region of the MSP domain of VAP-B and exhibits 77% homology to that of VAP-A (Fig. 1A). To exam-




FIG. 2. VAP-C binds to NS5B but not NS5A and interrupts the interaction of VAP-A and VAP-B with NS5B. (A) The expression plasmids encoding NS5A or VAP proteins (1 μ g each) were transfected into 293T cells after adjusting the total amounts of DNA to 2.0 μ g with empty plasmid. HA-tagged NS5A was coexpressed with either FLAG-tagged VAP-A, VAP-B, or VAP-C in 293T cells and immunoprecipitated (IP) with anti-HA antibody, and the resulting precipitates were immunoblotted using anti-FLAG or anti-HA antibody. (B) The expression plasmids encoding NS5B or VAP proteins (1 μ g each) were transfected into 293T cells after adjusting the total amounts of DNA to 3.0 μ g with empty plasmid. HA-tagged NS5B was coexpressed with either FLAG-tagged VAP-A or VAP-B in the presence or absence of FLAG-tagged VAP-C in 293T cells and immunoprecipitated (IP) with anti-HA antibody, and the resulting precipitates were immunoblotted using anti-FLAG or anti-HA antibody. One percent of the lysate was used as an input control. The data in each panel are representative of the results of three independent experiments. +, present.

ine whether VAP-C is capable of interacting with NS5B, as are VAP-A and VAP-B, HA-NS5B was coexpressed with FLAG-VAP-A, FLAG-VAP-B, or FLAG-VAP-C in 293T cells and was immunoprecipitated with anti-HA antibody (Fig. 2B). Although substantial amounts of FLAG-tagged VAP-A, VAP-B, and VAP-C were coexpressed, and although all three were coprecipitated with HA-NS5B at comparable levels, the interaction of HA-NS5B with FLAG-tagged VAP-A or VAP-B was impaired by the coexpression of VAP-C, while FLAG-VAP-C was coprecipitated with HA-NS5B instead of FLAG-tagged VAP-A or VAP-B. These results suggest that VAP-C is capable of binding to NS5B and that the expression of VAP-C interrupts the interactions of NS5B with VAP-A and VAP-B.

Expression of VAP-C impairs the replication of HCV. VAP-A and VAP-B are known to support the replication of HCV RNA (2, 7). To examine the effect of VAP-C on the replication of HCV, FLAG-VAP-C was expressed in HCV replicon cells, Huh 9-13, in which a subgenomic HCV RNA of the genotype 1b strain Con1 was autonomously replicating. Huh 9-13 cells transfected with a plasmid encoding FLAG-VAP-C were harvested periodically up to 72 h posttransfection. The levels of replication of viral RNA and expression of NS5A were determined by real-time PCR and immunoblot-

ting, respectively (Fig. 3). The expression of VAP-C reduced the intracellular RNA of the subgenomic HCV replicon in accordance with the incubation period after transfection with the expression plasmid of FLAG-VAP-C; the empty plasmid did not reduce the intracellular RNA (Fig. 3A). The expression of NS5A was gradually decreased and was undetectable at 72 h posttransfection, in contrast to the increase of VAP-C expression (Fig. 3B).

Next, to determine the effects of VAP-C expression on the replication of HCV, Huh 9-13 cells were transfected with 0 to 4 μ g of the expression plasmid encoding VAP-A, VAP-B, or VAP-C and the replication of the subgenomic HCV RNA was determined at 48 h posttransfection. Although the HCV replicon cells transfected with 4 μ g of a plasmid encoding FLAG-VAP-B exhibited enhancement of the RNA replication, those transfected with an equivalent amount of plasmid encoding FLAG-VAP-A or empty vector showed a slight reduction of HCV RNA replication. In contrast, the replicon cells transfected with a plasmid encoding FLAG-VAP-C exhibited a clear reduction of the HCV RNA replication in a dose-dependent manner (Fig. 3C). The expression of FLAG-tagged VAP-A, VAP-B, or VAP-C in the replicon cells was increased in correspondence with the amount of the transfected plasmid




FIG. 3. Expression of VAP-C impairs the replication of HCV. (A) HCV replicon cells (Huh 9-13) were transfected with 4 μg of the expression plasmids encoding FLAG-tagged VAP-C or empty vector, and the level of intracellular HCV RNA was determined at 0, 12, 24, 48, or 72 h posttransfection by real-time PCR after normalization with GAPDH mRNA. The value of HCV RNA at 0 h posttransfection in the cell line transfected with the empty plasmid is represented as 100%. Data in this panel are shown as means ± standard deviations. (B) Huh 9-13 cells were transfected with 4 μg of the plasmid encoding FLAG-tagged VAP-C or empty plasmid, and the levels of expression of NS5A, β-actin, and VAP-C were determined at 0, 12, 24, 48, or 72 h posttransfection by immunoblotting using anti-NS5A, anti-β-actin, or anti-FLAG tag antibody. (C) Huh 9-13 cells were transfected with 0 to 4 μg of the plasmids encoding FLAG-tagged VAP-A, VAP-B, or VAP-C or empty vector, and the level of intracellular HCV RNA was determined at 72 h posttransfection as described for panel A. Data in this panel are shown as means ± standard deviations. (D) Huh 9-13 cells treated as described for panel C were harvested at 72 h posttransfection, and the levels of expression of NS5A, β-actin, VAP-A, VAP-B, and VAP-C were determined by immunoblotting. The data in each panel are representative of the results of three independent experiments.

(Fig. 3D), and the expression of NS5A was suppressed in accordance with the expression of FLAG-VAP-C, whereas the expression of FLAG-VAP-A and FLAG-VAP-B exhibited no effect on the expression of NS5A. These results suggest that the expression of VAP-C impairs the replication of HCV RNA.

VAP-C exhibits no effect on the IRES-dependent translation. The expression of VAP-C was shown to suppress the replication of the HCV RNA replication of the replicon cells. Next, to determine the effect of VAPs on the translation of HCV RNA, the reporter plasmid encoding the *Renilla* luciferase gene under the control of the CMV promoter and the firefly luciferase gene under the IRES of HCV, PV, or EMCV,

in that order, was prepared as shown in Fig. 4. These reporter plasmids were introduced into Huh7OK1 cells 24 h after transfection of the expression plasmids encoding VAP-A, VAP-B, or VAP-C and harvested at 48 h posttransfection, and then the RLUs were determined. Although VAP-C exhibited a slight increase in the IRES-dependent translations of the HCV strains Con1 and JFH1, no significant effect of the expression of the VAPs on the HCV IRES-dependent translation was observed (Fig. 4A). Similarly, the expression of each of the VAPs in Huh7OK1 cells exhibited no significant effect on the IRES-dependent translation of PV or EMCV (Fig. 4B). These results indicate that the suppression of HCV RNA replication by the expression of




FIG. 4. VAP-C exhibits no effect on the viral IRES-dependent translation. (A) Top: structure of a reporter plasmid encoding the *Renilla* luciferase gene under the control of the CMV promoter and the firefly luciferase gene under the HCV IRES, in order. Bottom: the reporter plasmid was introduced into Huh7OK1 cells 24 h after transfection of the expression plasmids encoding VAP-A, VAP-B, or VAP-C, the cells harvested at 48 h posttransfection, and the RLU values determined after standardization with the expression of *Renilla* luciferase. (B) Top: structure of a reporter plasmid encoding the *Renilla* luciferase gene under the control of the CMV promoter and the firefly luciferase gene under the PV or EMCV IRES, in order. Bottom: each of the reporter plasmids was introduced into Huh7OK1 cells, and the RLU values were determined as described for panel A. Data in this figure are shown as the means \pm standard deviations.

VAP-C was not due to the suppression of the IRES-dependent translation of the viral RNA genome.

VAP-C impairs HCV propagation. To examine the effect of VAP expression on HCV propagation, Huh7OK1 cells transfected with the expression plasmids encoding VAP-A, VAP-B, or VAP-C were infected with JFH1 virus, and the levels of production of the viral RNA, core protein, and infectious particles were determined at 96 h postinfection. The production of intracellular and extracellular viral RNA was increased up to 10 to 30 times and 2 to 3 times, respectively, by the expression of VAP-A or VAP-B whereas it was clearly decreased in a dose-dependent manner by the expression of VAP-C (Fig. 5A). Although the extracellular core protein was increased from 0.6 to 2.6 nmol/liter by the expression of VAP-A or VAP-B, as seen in the production of viral RNA, the intracellular core protein showed only a marginal increase (40 to 65

nmol/liter) (Fig. 5A). Although the reason for the discrepancy between the intracellular production of viral RNA and core protein is not known at the moment, some mechanisms other than RNA translation might be involved, because VAP expression exhibited no effect on the HCV IRES-dependent translation, as shown in Fig. 4A. In contrast to the enhancement of core protein production by the expression of VAP-A or VAP-B, the expression of VAP-C significantly reduced both the intracellular and extracellular expression of the core protein (Fig. 5A). Furthermore, the production of infectious particles in the culture supernatants of Huh7OK1 cells infected with JFH1 virus was slightly enhanced by the expression of VAP-A or VAP-B, whereas it was suppressed by the expression of VAP-C (Fig. 5A). To further confirm the effects of VAPs on the expression of HCV proteins, Huh7OK1 cells transfected with various amounts of the expression plasmids of VAP-A, VAP-B, or VAP-C and infected with the JFH1 virus were examined by immunoblotting (Fig. 5B). Although the expression of VAP-A or VAP-B exhibited no effect on NS5A expression, VAP-C expression clearly decreased the expression of NS5A in a dose-dependent manner. These results clearly indicate that the expression of VAP-C negatively regulates HCV propagation. Overexpression of VAP-C did not affect the endogenous expression of VAP-A or VAP-B (Fig. 5C), suggesting that suppression of HCV propagation by VAP-C is not due to the reduction of VAP-A or VAP-B expression.

Lack of VAP-C expression in human livers. VAP-C consists of the first 70 amino acid residues of VAP-B and the subtype-specific 29 amino acid residues derived from frameshift (Fig. 1A). The VAP-C-specific antibody generated by immunization with the peptide corresponding to the residues from 86 to 98 clearly detected VAP-C but neither VAP-A nor VAP-B in cells transfected with expression plasmids encoding FLAG-tagged VAP-A, VAP-B, or VAP-C (Fig. 6A). To determine the distribution of VAPs in human organs, the pool lysates of various organs prepared from several people were examined by immunoblotting (Fig. 6B). Expression of VAP-A was detected clearly in the kidney, lung, prostate, and liver; slightly in the duodenum, uterus, vagina, and bladder; and barely in the small intestine and stomach. VAP-B was detected clearly in the bladder, kidney, and prostate and slightly in the duodenum, small intestine, uterus, vagina, and liver. Expression of VAP-C was detected clearly in the stomach, uterus, kidney, and bladder; slightly in the duodenum, small intestine, and prostate; and barely detected in the vagina, lung, and liver. Several bands smaller than the expected size of VAP-C were observed in the stomach, duodenum, small intestine, uterus, vagina, prostate, and bladder. Because the main target of HCV replication is thought to be the liver, we next examined the expression of VAPs in individual human liver samples. VAP-A and VAP-B were clearly detected in the liver tissues obtained from chronic hepatitis C patients and a healthy donor, but no expression of VAP-C was detected (Fig. 6C). These results suggest that the expression of VAP-C may participate in the determination of tissue tropism of HCV propagation.

Substitution of Ser for Pro⁵⁶ in VAPs leads to suppression of HCV replication. A single mutation of Pro⁵⁶ to Ser (P56S) of VAP-B has been reported to be highly associated with amyotrophic lateral sclerosis (ALS), and the P56S mutation of VAP-B but not of VAP-A has been shown to induce large